Bioaffinity Technologies Warrant Stock Current Valuation
| BIAFW Stock | USD 0.57 0.13 18.57% |
Valuation analysis of BioAffinity Technologies helps investors to measure BioAffinity Technologies' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to -1.6 in 2024. Enterprise Value Multiple is likely to drop to -1.6 in 2024.
Overvalued
Today
Please note that BioAffinity Technologies' price fluctuation is out of control at this time. Calculation of the real value of BioAffinity Technologies is based on 3 months time horizon. Increasing BioAffinity Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BioAffinity stock is determined by what a typical buyer is willing to pay for full or partial control of bioAffinity Technologies Warrant. Since BioAffinity Technologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioAffinity Stock. However, BioAffinity Technologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.57 | Real 0.55 | Hype 0.57 | Naive 0.34 |
The intrinsic value of BioAffinity Technologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BioAffinity Technologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of bioAffinity Technologies Warrant helps investors to forecast how BioAffinity stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioAffinity Technologies more accurately as focusing exclusively on BioAffinity Technologies' fundamentals will not take into account other important factors: bioAffinity Technologies Warrant Company Current Valuation Analysis
BioAffinity Technologies' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
BioAffinity Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for BioAffinity Technologies is extremely important. It helps to project a fair market value of BioAffinity Stock properly, considering its historical fundamentals such as Current Valuation. Since BioAffinity Technologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioAffinity Technologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioAffinity Technologies' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, bioAffinity Technologies Warrant has a Current Valuation of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
BioAffinity Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioAffinity Technologies' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioAffinity Technologies could also be used in its relative valuation, which is a method of valuing BioAffinity Technologies by comparing valuation metrics of similar companies.BioAffinity Technologies is currently under evaluation in current valuation category among its peers.
BioAffinity Fundamentals
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.7 | ||||
| Profit Margin | (1.19) % | ||||
| Operating Margin | (0.87) % | ||||
| Revenue | 2.53 M | ||||
| EBITDA | (7.63 M) | ||||
| Net Income | (7.94 M) | ||||
| Cash And Equivalents | 214.4 K | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.58 M | ||||
| Current Ratio | 0.02 X | ||||
| Book Value Per Share | 0.52 X | ||||
| Cash Flow From Operations | (6.04 M) | ||||
| Number Of Employees | 75 | ||||
| Beta | 3.12 | ||||
| Total Asset | 8.22 M | ||||
| Retained Earnings | (44.6 M) | ||||
| Working Capital | 1.72 M | ||||
| Net Asset | 8.22 M |
About BioAffinity Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze bioAffinity Technologies Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAffinity Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of bioAffinity Technologies Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.